PMID- 18613768
OWN - NLM
STAT- MEDLINE
DCOM- 20080828
LR  - 20191027
IS  - 1744-7682 (Electronic)
IS  - 1471-2598 (Linking)
VI  - 8
IP  - 8
DP  - 2008 Aug
TI  - Apomab: an agonist monoclonal antibody directed against Death Receptor 
      5/TRAIL-Receptor 2 for use in the treatment of solid tumors.
PG  - 1167-76
LID - 10.1517/14712598.8.8.1167 [doi]
AB  - BACKGROUND: Apomab is a pro-apoptotic anticancer agonist monoclonal antibody 
      against Death receptor 5 (DR5)/TNF-related apoptosis inducing ligand-receptor 2 
      (TRAIL-R2). OBJECTIVE: To review available preclinical and clinical data and 
      compare Apomab with similar agents. METHODS: Manuscripts were identified (PubMed) 
      using the terms TRAIL-R2, DR5 and Apomab. Abstracts from major oncology meetings 
      in 2005 - 2008 were hand-searched. RESULTS/CONCLUSION: Apomab demonstrates 
      preclinical activity against a range of solid tumors, both as monotherapy and in 
      combination with cytotoxics. Clinical data are limited but Apomab exposures 
      appear compatible with intermittent dosing alongside standard chemotherapy 
      regimens. Transaminitis has been noted in 1 out of 37 patients but the true 
      frequency and severity of this and other toxicities cannot yet be determined. 
      Apomab has shown early signs of anticancer activity in heavily pretreated 
      patients. Several similar agents are at similar stages of development. No direct 
      comparisons have yet been undertaken but potential differences between these 
      agents are discussed.
FAU - Camidge, D Ross
AU  - Camidge DR
AD  - Developmental Therapeutics and Thoracic Oncology Programs, Department of Medical 
      Oncology, University of Colorado Denver, Aurora, CO 80045-0508, USA. 
      Ross.Camidge@UCHSC.edu
LA  - eng
PT  - Journal Article
PL  - England
TA  - Expert Opin Biol Ther
JT  - Expert opinion on biological therapy
JID - 101125414
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Receptors, TNF-Related Apoptosis-Inducing Ligand)
RN  - 703KLX5LXZ (apomab)
SB  - IM
MH  - Animals
MH  - Antibodies, Monoclonal/immunology/*pharmacology/therapeutic use
MH  - Antineoplastic Agents/adverse 
      effects/immunology/pharmacokinetics/*pharmacology/therapeutic use
MH  - Humans
MH  - Neoplasms/*drug therapy
MH  - Receptors, TNF-Related Apoptosis-Inducing Ligand/*agonists/immunology
EDAT- 2008/07/11 09:00
MHDA- 2008/08/30 09:00
CRDT- 2008/07/11 09:00
PHST- 2008/07/11 09:00 [pubmed]
PHST- 2008/08/30 09:00 [medline]
PHST- 2008/07/11 09:00 [entrez]
AID - 10.1517/14712598.8.8.1167 [doi]
PST - ppublish
SO  - Expert Opin Biol Ther. 2008 Aug;8(8):1167-76. doi: 10.1517/14712598.8.8.1167.